Yi-Yun Huang
Yi-Yun Huang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hong-Guang He
Department of Nephrology, The People’s Hospital of Guangxi Zhuang Autonomous Region
2 shared publications - Kun Ye
Department of Nephrology, The People’s Hospital of Guangxi Zhuang Autonomous Region
2 shared publications - Qin-Qing Liang
Department of Pathology, The People’s Hospital of Guangxi Zhuang Autonomous Region
2 shared publications - Qiu-Rong Ye
Department of Pathology, The People’s Hospital of Guangxi Zhuang Autonomous Region
2 shared publications - Qiu-Xia Wu
Department of Nephrology, The People’s Hospital of Guangxi Zhuang Autonomous Region
2 shared publications - Yanwu You
Department of Nephrology, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
2 shared publications
Latest Publications
- Open Access
- 9 April 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2653964
Predictive value of CD44 in membranous nephropathy with focal segmental glomerular sclerosis lesions treated with calcineurin inhibitors
Calcineurin inhibitors (CNIs) are effective immunosuppressive agents for idiopathic membranous nephropathy (iMN). Focal segmental glomerular sclerosis (FSGS) lesions, frequently observed in MN, have been identified as indicators of poor prognosis. This retrospective study enrolled 71 patients with biopsy-proven iMN accompanied by FSGS lesions, all of whom were initially treated with CNIs. This study identified independent risk factors for renal function progression and assessed the predictive significance of CD44. The primary outcome was defined as a 50% decline in the eGFR. Fifty-eight patients (81.7%) had CD44+ visceral epithelial cells (VECs), with 36 (36/71, 50.7%) demonstrating a linear positive pattern, of whom 19 patients showed a strong positive (3+) linear distribution in VECs. The patients with a strong linear distribution of CD44+ VECs had a higher rate of progression to the primary outcome (13/19 vs. 6/52, p < 0.001). The model based on age (OR, 1.134; p = 0.004), failure to achieve CR with CNIs treatment (non-CR) (OR, 6.924; p = 0.042), and strong linear CD44+ VECs (OR, 37.139; p < 0.001) showed good discrimination in predicting renal function decline, with a receiver operating characteristic AUC of 0.929 (0.871-0.986) (p < 0.001). Therefore, patients with strong linear CD44+ VECs showed a lower remission rate and a higher rate of progression to the primary outcome. The model, which incorporated age, non-CR status, and strongly linear CD44+ VECs, demonstrated effective discrimination in predicting renal function deterioration.
- 9 April 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2653964
Open AccessPredictive value of CD44 in membranous nephropathy with focal segmental glomerular sclerosis lesions treated with calcineurin inhibitors
Calcineurin inhibitors (CNIs) are effective immunosuppressive agents for idiopathic membranous nephropathy (iMN). Focal segmental glomerular sclerosis (FSGS) lesions, frequently observed in MN, have been identified as indicators of poor prognosis. This retrospective study enrolled 71 patients with biopsy-proven iMN accompanied by FSGS lesions, all of whom were initially treated with CNIs. This study identified independent risk factors for renal function progression and assessed the predictive significance of CD44. The primary outcome was defined as a 50% decline in the eGFR. Fifty-eight patients (81.7%) had CD44+ visceral epithelial cells (VECs), with 36 (36/71, 50.7%) demonstrating a linear positive pattern, of whom 19 patients showed a strong positive (3+) linear distribution in VECs. The patients with a strong linear distribution of CD44+ VECs had a higher rate of progression to the primary outcome (13/19 vs. 6/52, p < 0.001). The model based on age (OR, 1.134; p = 0.004), failure to achieve CR with CNIs treatment (non-CR) (OR, 6.924; p = 0.042), and strong linear CD44+ VECs (OR, 37.139; p < 0.001) showed good discrimination in predicting renal function decline, with a receiver operating characteristic AUC of 0.929 (0.871-0.986) (p < 0.001). Therefore, patients with strong linear CD44+ VECs showed a lower remission rate and a higher rate of progression to the primary outcome. The model, which incorporated age, non-CR status, and strongly linear CD44+ VECs, demonstrated effective discrimination in predicting renal function deterioration.
- Open Access
- 19 September 2023
- Published by Taylor & Francis in Renal Failure
- Vol. 45 (2) , 2253930
Calcineurin inhibitors or cyclophosphamide in the treatment of membranous nephropathy superimposed with FSGS lesions: a retrospective study from China
Cyclophosphamide (CTX) and calcineurin inhibitors (CNIs) based regimens are recommended as immunosuppressive therapies for patients with idiopathic membranous nephropathy (IMN). Focal and segmental glomerular sclerosis (FSGS) lesions, which are common in membranous nephropathy (MN), are poor predictors of outcome. This study compared the differences of prognosis between two regimens in patients with IMN combined with FSGS lesions. This retrospective study enrolled 108 patients with biopsy-proven IMN, accompanied with FSGS lesions, nephrotic syndrome and an estimated glomerular filtration rate (eGFR)≥60 mL/min/1.73 m2 who were treated with CTX or CNIs. We used propensity score matching (PSM) for balancing the confounding variables. During follow-up, 10 patients (10/55 [18.2%]; nine males) in the CNIs group showed a 50% decline in eGFR; eight had a not otherwise specified variant. Patients initially treated with CNIs had a significantly higher risk of progression to the primary outcome and a lower probability of complete or total remission. The relapse rate was higher in patients who initially received CNIs- than in those who received CTX-based treatment. Before PSM, age and 24-h urine protein level differed significantly between the groups. The PSM model included data from 72 patients. Worse outcomes were also noted among patients who initially received CNIs than those who received CTX-based treatments after matching. Patients with MN combined with FSGS lesions have a higher risk of renal functional decline and a higher rate of relapse after CNIs than after CTX therapy.
- 19 September 2023
- Published by Taylor & Francis in Renal Failure
- Vol. 45 (2) , 2253930
Open AccessCalcineurin inhibitors or cyclophosphamide in the treatment of membranous nephropathy superimposed with FSGS lesions: a retrospective study from China
Cyclophosphamide (CTX) and calcineurin inhibitors (CNIs) based regimens are recommended as immunosuppressive therapies for patients with idiopathic membranous nephropathy (IMN). Focal and segmental glomerular sclerosis (FSGS) lesions, which are common in membranous nephropathy (MN), are poor predictors of outcome. This study compared the differences of prognosis between two regimens in patients with IMN combined with FSGS lesions. This retrospective study enrolled 108 patients with biopsy-proven IMN, accompanied with FSGS lesions, nephrotic syndrome and an estimated glomerular filtration rate (eGFR)≥60 mL/min/1.73 m2 who were treated with CTX or CNIs. We used propensity score matching (PSM) for balancing the confounding variables. During follow-up, 10 patients (10/55 [18.2%]; nine males) in the CNIs group showed a 50% decline in eGFR; eight had a not otherwise specified variant. Patients initially treated with CNIs had a significantly higher risk of progression to the primary outcome and a lower probability of complete or total remission. The relapse rate was higher in patients who initially received CNIs- than in those who received CTX-based treatment. Before PSM, age and 24-h urine protein level differed significantly between the groups. The PSM model included data from 72 patients. Worse outcomes were also noted among patients who initially received CNIs than those who received CTX-based treatments after matching. Patients with MN combined with FSGS lesions have a higher risk of renal functional decline and a higher rate of relapse after CNIs than after CTX therapy.